The Utilization of Spironolactone in Heart Failure Patients at a Tertiary Hospital in Saudi Arabia
| Autor: | Mohammed A. Alqahtani, Numan Alabdan, Haifa Aljaafary, Abdulmalik S Alotaibi, Abdullah M Alotaibi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Cardiology heart failure 030204 cardiovascular system & hematology Sudden death spironolactone utilization 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Primary aldosteronism Internal medicine medicine Internal Medicine saudi arabia mineralocorticoid receptor antagonist Stroke Creatinine Ejection fraction business.industry General Engineering Furosemide medicine.disease chemistry Heart failure Spironolactone business 030217 neurology & neurosurgery Family/General Practice aldosterone antagonists medicine.drug |
| Zdroj: | Cureus |
| ISSN: | 2168-8184 |
| Popis: | Introduction: Heart failure (HF) has high morbidity and mortality rates. Spironolactone has shown a 30% reduction in all-cause mortality, reduction in hospitalizations, and sudden death. However, data shows low use of spironolactone in HF patients. We aim to assess spironolactone utilization in HF reduced Ejection Fraction (HFrEF) patients and to identify the factors affecting its prescribing. Methods: A retrospective cross-sectional study of patients diagnosed with HF from January 2016 to January 2017 conducted at King Abdulaziz Medical City-Riyadh. Inclusion criteria: all adult HFrEF 30 mL/min/1.73m2 and potassium |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|